InSite Vision delisted by Amex - San Francisco Business Times:

tenganmodooo1324.blogspot.com
million since 2004, has been removedc from the AmericanStock Exchange. The exchange cited the company’s including $5.5 million in the first and a stock price that has ranged from 59 cents to 17 centss over the pastsix months, according to an SEC The filing comes a week after InSite said won Food and Drug Administrationm approval for Besivance, which uses a synthetic polymer developed by InSite now is trader over the counter as InSite has one product on the U.S. market — the pink-eye treatmengt AzaSite — and that was approved in March in It also has signexd distribution deals inSoutn Korea, Turkey and China as well as four South American countries.
InSite also plans to enterr a Phase III trial of atopical antibiotic/corticosteroid product to treat eyelid infection and inflammation in adults. Yet the company said in Marc that it would fire more than halfits staff, bringing its workforcr to under 20 people. A Texas venture capita firm, , last summer led a shareholder coup that replaces the board of directors and broughf about the resignationof S. Kumar Chandrasekaran, the company’s chairmann and CEO. The American Stock Exchanged initially notified InSite in December that it was not in compliancde withexchange rules. InSite the next montgh submitted a plan to regain compliance but that was rejected in Februaryt bythe exchange.
The company appealec and on April 8, the company learned that the exchangr deniedthe appeal.